Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
ZolgensmaⓇ grew 48% in Q2, potentially transformative efficacy in
pre-symptomatic SMA
Sales evolution
USD m
Ex-US
US
+48%
315
205
209
100
Q2 highlights
■ Continued strong sales growth with expanding access in Europe and emerging markets
■ Stable US business, driven by incident patients
Approval in 41 countries; access pathways in 19 countries
■ 1.4k+ patients have been treated with ZolgensmaⓇ worldwide¹
Future growth drivers
☐
☐
105
106
Q2 2020
Q2 2021
Reimbursement: Implementation of H1 milestones (e.g. NHS)² and global expansion
■ Newborn screening: met target in US of >80%, on track for 20% in EU by end 2021
New data reinforce strong clinical benefit³
Age-appropriate development when used presymptomatically (SPR1NT) and
consistent, significant benefit in symptomatic children (STR1VE-EU)
■ Reinforces ZolgensmaⓇ as foundational therapy for both presymptomatic and
symptomatic children with SMA
1. Commercially, via managed access programs and in clinical trials. 2. NHS: National Health Service in England. 3. Presented at European Academy of Neurology (EAN) 2021.
22 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation